Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): a randomised phase 3 trial
Jaafar Bennouna, Javier Sastre, Dirk Arnold et al. · The Lancet Oncology · 2012
Cited by 1,164 works. doi:10.1016/s1470-2045(12)70477-1
Authors
- Jaafar Bennouna
- Javier Sastre
- Dirk Arnold
- Pia J. Osterlund
- Richard Greil
- Eric Van Cutsem
- Roger von Moos
- José María Viéitez
- Olivier Bouché
- Christophe Borg
- Claus-Christoph Steffens
- Vicente Alonso-Orduña
- Christoph L. Schlichting
- Irmarie Reyes‐Rivera
- Belguendouz Bendahmane
- Thierry André
- Stefan Kubicka
References
- Sequential Treatment Assignment with Balancing for Prognostic Factors in the Controlled Clinical Trial
- Bevacizumab plus Irinotecan, Fluorouracil, and Leucovorin for Metastatic Colorectal Cancer
- Cetuximab Monotherapy and Cetuximab plus Irinotecan in Irinotecan-Refractory Metastatic Colorectal Cancer
- Phase II, Randomized Trial Comparing Bevacizumab Plus Fluorouracil (FU)/Leucovorin (LV) With FU/LV Alone in Patients With Metastatic Colorectal Cancer
- FOLFIRI Followed by FOLFOX6 or the Reverse Sequence in Advanced Colorectal Cancer: A Randomized GERCOR Study
- Bevacizumab in Combination With Oxaliplatin-Based Chemotherapy As First-Line Therapy in Metastatic Colorectal Cancer: A Randomized Phase III Study
- Bevacizumab in Combination With Oxaliplatin, Fluorouracil, and Leucovorin (FOLFOX4) for Previously Treated Metastatic Colorectal Cancer: Results From the Eastern Cooperative Oncology Group Study E3200
- Modes of resistance to anti-angiogenic therapy
- Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity
- Breast Cancer, Version 4.2017, NCCN Clinical Practice Guidelines in Oncology